Vatelizumab Setback Dulls Glenmark's Q2 Growth
This article was originally published in Scrip
Glenmark Pharmaceuticals Ltd reported overall growth in the second quarter ended September, but Sanofi's decision to end development of the Indian firm's monoclonal antibody, vatelizumab (GBR-500), took some sheen off its good run.
You may also be interested in...
While deal-making in the Asian pharma space shows no signs of slowing down, the past few months have been marked by a series of high-profile cases involving the return of rights by licensees or setbacks in clinical trials. Scrip's regional team looks at some of the factors at work.
Tildrakizumab debuts in Japan, marking a key milestone for Sun Pharma, though heavyweight competitors including same class rival Skyrizi are already available on the market there.
Redirection of healthcare resources to tackle COVID-19 is posing huge challenges for TB care and researchers in the area. Companies like J&J have stepped in to support, among other aspects, innovative community-based solutions to ensure continuity of care for drug resistant-TB patients amid the pandemic.